MOREPEN LABORATORIES
|
MOREPEN LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.88 | 0.76 | 2.13 | 2.16 | 0.75 |
| CEPS(Rs) | 2.55 | 1.30 | 2.71 | 2.83 | 1.57 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 16.58 | 14.73 | 11.56 | 8.47 | 6.32 |
| Tax Rate(%) | 28.65 | 30.63 | 19.75 | 1.44 | 14.14 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.38 | 5.61 | 8.84 | 9.98 | 8.03 |
| EBIT Margin(%) | 8.23 | 4.07 | 8.35 | 8.44 | 4.82 |
| Pre Tax Margin(%) | 8.01 | 3.93 | 8.19 | 8.29 | 4.58 |
| PAT Margin (%) | 5.72 | 2.73 | 6.57 | 8.17 | 3.94 |
| Cash Profit Margin (%) | 7.70 | 4.70 | 8.36 | 10.72 | 8.26 |
| Performance Ratios | |||||
| ROA(%) | 8.04 | 3.55 | 10.55 | 12.76 | 5.25 |
| ROE(%) | 12.08 | 5.93 | 21.79 | 29.20 | 12.50 |
| ROCE(%) | 16.82 | 8.40 | 24.86 | 27.13 | 12.05 |
| Asset Turnover(x) | 1.41 | 1.30 | 1.60 | 1.56 | 1.33 |
| Sales/Fixed Asset(x) | 2.65 | 2.23 | 2.49 | 1.72 | 1.04 |
| Working Capital/Sales(x) | 3.47 | 3.26 | 5.57 | 9.66 | 41.15 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.38 | 0.45 | 0.40 | 0.58 | 0.96 |
| Receivable days | 63.50 | 66.16 | 51.04 | 49.10 | 58.07 |
| Inventory Days | 51.55 | 64.98 | 53.23 | 48.20 | 49.78 |
| Payable days | 93.67 | 98.32 | 86.93 | 94.60 | 118.53 |
| Valuation Parameters | |||||
| PER(x) | 22.36 | 33.94 | 17.20 | 14.89 | 12.78 |
| PCE(x) | 16.53 | 19.71 | 13.52 | 11.35 | 6.09 |
| Price/Book(x) | 2.54 | 1.74 | 3.17 | 3.80 | 1.51 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.26 | 0.90 | 1.11 | 1.17 | 0.47 |
| EV/Core EBITDA(x) | 12.32 | 14.96 | 10.98 | 10.68 | 5.18 |
| EV/EBIT(x) | 15.29 | 22.20 | 13.33 | 13.91 | 9.82 |
| EV/CE(x) | 2.43 | 1.65 | 1.61 | 1.63 | 0.61 |
| M Cap / Sales | 1.27 | 0.93 | 1.13 | 1.22 | 0.50 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 19.25 | -8.36 | 30.20 | 39.27 | 11.00 |
| Core EBITDA Growth(%) | 101.47 | -45.36 | 20.05 | 67.42 | 9.56 |
| EBIT Growth(%) | 140.97 | -55.29 | 28.74 | 144.09 | 31.34 |
| PAT Growth(%) | 149.82 | -61.96 | 4.73 | 189.14 | 16.43 |
| EPS Growth(%) | 148.62 | -64.44 | -1.40 | 189.15 | 16.40 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 |
| Current Ratio(x) | 2.21 | 2.35 | 1.61 | 1.30 | 1.06 |
| Quick Ratio(x) | 1.59 | 1.64 | 1.00 | 0.87 | 0.66 |
| Interest Cover(x) | 37.50 | 29.15 | 53.22 | 56.09 | 20.71 |
| Total Debt/Mcap(x) | 0.01 | 0.02 | 0.01 | 0.01 | 0.03 |
Compare Financial Ratios of peers of MOREPEN LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MOREPEN LABORATORIES | ₹4,726.5 Cr | -1.5% | -3.1% | 155.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹453,486.0 Cr | -0.6% | 1.3% | 65.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,321.0 Cr | -1.1% | 11.4% | 64% | Stock Analytics | |
| CIPLA | ₹125,852.0 Cr | -2.3% | -6.8% | 33.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,799.0 Cr | 1.5% | 1% | 22.9% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹102,726.0 Cr | -4.2% | -8.1% | 72.3% | Stock Analytics | |
MOREPEN LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MOREPEN LABORATORIES | -1.5% |
-3.1% |
155.5% |
| SENSEX | -0.7% |
-2.4% |
22% |
You may also like the below Video Courses
